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to establish the exact correlation with PAP.
Study design: Patients were eligible if they were admitted with a
clinical and radiological diagnosis of interstitial lung disease. All patients
underwent to: echocardiography and BNP. We included in this study
120 consecutive patients affected by interstitial lung disease. Patients
revealing PAPs N 40 mm Hg (43 patients) were then submitted to RC
invasivemeasurement to calculate PAPs, PAPmean and pulmonary vas-
cular resistance (PVR). Written consent was provided by each patient.
Patients were recruited from ARTEMIS-HP trial (www.clinicaltrials.
gov: ID number NCT00879229).Natriuretic peptides (B-type natriuretic peptide [BNP] and NT pro-
BNP) are proposed biomarkers to differentiate between cardiac and pul-
monary causes of acute dyspnea [1]. Some emerging data proposed the
use in respiratory disease and particularly in patientswith acute pulmo-
nary embolism and pulmonary hypertension (PH) [2].
Prevalence of pulmonary hypertension (PH) in interstitial lung dis-
eases (ILD) is higher in patients with severe ﬁbrosis but it may develop
at any stage of the disease [3,4]. Early recognition is frequently delayed
from symptoms onset and diagnosis. For all these reasons the detection
of pulmonary arterial pressure (PAP) in patients affected to ILD is critical
for diagnosis and clinical assessment [5]. The current gold standard for
PH assessment is invasive right heart catheterization, however this proce-
dure is prone to increased risk of complications and it should be carried
out in patients with evidence of PH previously identiﬁed by non-invasive
investigation [6]. Currently, the optimal tool to measure PH remains un-
clear. The most appropriate, recognized method to detect PAP noninva-
sively is trans-thoracic echocardiography, which demonstrated a good
correlation with invasive measurement [7]. We hypothesized that the
combination of echocardiography and BNP measurement may provide
a better detection of PH in patients with ILD. Thus the aims of this
study were: 1—to determine the accuracy of echo measurement and
BNP assay in the detecting PH through building an algorithm modeldicine and Metabolic Diseases,
Siena, Italy.
.and 2—to compare BNP and echo values with invasive measurement
Laboratory analysis: Within 24 h from enrolment we measured, in
all patients, BNP levels. Plasma BNP was measured with Triage BNP
Test (Biosite Inc., San Diego, CA, USA); this test is an immunoassay in
a single-use plastic cartridge ﬂuorescently labeledmonoclonal antibody
against BNP labeled with a ﬂuorescent dye and BNP. The level of BNP in
12 healthy subjects was not higher than 80 pg/mL.
Echocardiography: Right ventricular (RV) dimension and pulmo-
nary pressure (PAPs and PAP mean) were estimated following the
American Society of Echocardiography criteria [8].
Invasivemeasurement: For a subgroupof patientswith echocardio-
graphic evidence of PH, hemodynamic results of right heart catheteriza-
tion were obtained, measuring pulmonary artery pressures, pulmonary
artery WEDGE pressures and vascular resistance [9].
Endpoints: 1— To establish correlations among BNP and echocardio-
graphicmeasurements in the detecting PH, 2— to calculate the sensibility
and accuracy power of the echocardiographic and BNP assessments in
recognizing pulmonary hypertension, and 3 — to compare BNP and
echo values with invasivemeasurement to establish the exact correlation
with PH, deﬁned as PAP mean N 25 mm Hg.
Patients' characteristics: 109 patients (age 62 + 11; 46 males)
fulﬁlled the inclusion criteria. ILD diagnoses included: idiopathic pulmo-
nary ﬁbrosis (IPF; n = 72), sarcoidosis (n = 15), systemic sclerosis
(n = 4), extrinsic allergic alveolitis (EAA; n = 2), smoking-related inter-
stitial lung disease or drug-related interstitial ﬁbrosis (n = 15) and
Langerhans' cell histiocytosis (n = 1). Among these patients there were
43 subjects with PAPs ≥ 40 mm Hg. All patients with PAPs N 40 mm Hg
underwent RC to measure invasive parameters PAPs, PAP mean,
WEDGE pressure and PVR. Of 43 catheterized patients, 34 showed PH,
deﬁned as PAP mean N 25 mm Hg. BNP mean in all population was of
63 pg/mL [CI: 32–96] (Table 1).
Table 1
Baseline characteristics of all patients with ILD included in our study. Abbreviations: BNP:
B-type natriuretic peptide; FE: Ejection fraction; ILD: Interstitial lung disease; PAPd: End-
diastolic pulmonary arterial pressure; PAPs: Pulmonary systolic arterial pressure; PAPm:
Pulmonary arterial pressure mean; PVR: Pulmonary vascular resistance; TAPSE: Tricuspid
annular plane systolic excursion.
Number of the patients 109
Age (year) 63 ± 11
Weight (Kg) 77 ± 14
Height (cm) 168 ± 11
Gender (n)
Male 57
Female 52
Risk factors and comorbidity (%)
Hypertension 26%
Diabetes 49%
Dyslipidemia 32%
Osteoporosis 76%
Interstitial lung disease (n)
Pulmonary idiopathic ﬁbrosis 72
Sarcoidosis 15
Extrinsic allergic alveolitis 4
Systemic sclerosis 2
Langherans cell hystiocytosis 1
Other 15
Lung diseases' treatment (%)
Corticosteroids therapy 94
Immunosuppressive therapy 17
Echocardiographic parameters
FE (%) 55 ± 3
End-diastolic ventricular diameter (mm) 36 ± 7
Right atrium area (cm2) 20 ± 3
Caliber inferior cave vein (mm) 17 ± 5
PAPs (mm Hg) 37 ± 12
PAPs ≥ 40 mm Hg (n) 43
PAP mean (mm Hg) 18 ± 7
PAP mean ≥ 20 mm Hg (n) 29
TAPSE (mm) 22 ± 3
TAPSE ≤ 20 mm (n) 31
Invasive Measurements (43 patients)
PAPs (mm Hg) 45 ± 14
PAP m (mm Hg) 25 ± 10
WEDGE pressure (mm Hg) 12 ± 5
PVR (hru) 3,21 ± 2.20
Pulmonary hypertension deﬁned as invasive PAP
mean ≥ 25 mm Hg (n)
34
BNP (pg/mL) 63 [32–96]
Fig. 1. Receiver operating characteristic (Roc) curve analysis in predicting patients with
PH. Logistic regression analysis evaluating ability of echocardiographic parameters (PAPs
and PAP mean) and BNP to detect PH. Abbreviations: AUC: Area under the curve; BNP:
B-type natriuretic peptide; CI: Conﬁdence interval; PAPs: Pulmonary systolic arterial pres-
sure; PAPm: Pulmonary arterial pressuremean; PH: Pulmonary hypertension; TAPSE: Tri-
cuspid annular plane systolic excursion.
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creased compared to patients without pulmonary hypertension
(162 ± 96 vs 18 ± 7 pg/ml p = 0,004), PAPd N 20 mm Hg (205 ±
118 vs 38 ± 19 pg/mL p = 0,001) and PAP mean b 25 mm Hg
(128 ± 84 vs 33 ± 12 pg/ml p b 0.001). BNP was also signiﬁcantly
increased in patients with right ventricular dysfunctionTable 2
T-test evaluating BNP value changes relation to echocardiographic and invasive parameters. Ab
sure; PAPs: Pulmonary systolic arterial pressure; PAPm: Pulmonary arterial pressure mean; TA
All patients (109)
Echocardiographic parameters BNP mean (pg/mL) Echoca
PAPs b 40 mm Hg 18 ± 7 PAPs ≥
PAPd b 20 mm Hg 39 ± 19 PAPd ≥
PAP mean b 25 mm Hg 33 ± 12 PAP me
End diastolic diameter b 38 mm 36 ± 24 End dia
TAPSE N 16 mm 21 ± 13 TAPSE
Catheterized patients (43)
Invasive measurement BNP mean (pg/mL) Invasiv
PAPs b 40 mm Hg 39 ± 17 PAP ≥
PAP mean b25 mm Hg 25 ± 18 PAP me
WEDGE pressure b 14 mm Hg 43 ± 31 WEDGE(TAPSE b 16mm) (153±104 vs 21±13 pg/ml p b 0.001) and dilatation
of RV (end-diastolic diameter ≥ 38 mm) (179 ± 115 vs 36 ± 24 pg/ml
p b 0.001).
In patients with invasive PAPs N 40 mm Hg and with invasive PAP
mean N25 mm Hg, (n. 34) BNP levels were signiﬁcantly increased re-
spect patients with invasive PAPs b 40 mm Hg (169 ± 110 vs 39 ±
17 pg/ml p b 0,02) and with invasive PAP mean b 25 mm Hg (206 ±
127 vs 25 ± 18 pg/ml p b 0.005). In patients with WEDGE
pressure ≥ 14 mm Hg, BNP levels were signiﬁcantly higher than
patients with WEDGE pressure b 14 mm Hg (207 ± 151 vs 43 ±
31 pg/mL; p = 0.01) (Table 2).
Diagnostic prediction for PH: The Roc curve analysis showed that
BNP (AUC 0.87; [CI: 0.77–0.98]; p = 0.001), PAP mean (AUC 0.89; [CI:
0.80–0.98]; p = 0.001) and PAPs (AUC 0.81; [CI: 0.76–0.98]; p =
0.001)were all able to detect PH. A cut-off BNP value≥ 50 pg/ml, recog-
nized patients with PH, with good sensitivity (77%) and good speciﬁcity
(81%) (Fig. 1). Regression analysis of the above parameters conﬁrmed
that echocardiographic measurements (PAPs, PAP mean and TAPSE)
and BNP values were signiﬁcantly related (Table 3).
Early detection of PH in patients with ILD is determinative to bet-
ter establish prognostic impact of lung disease and to begin a speciﬁc
treatment. The current European Society of Cardiology (ESC)/
European Respiratory Society (ERS) guidelines recommend annual
echocardiographic screening in symptomatic patients [10]. Our studybreviations: BNP: B-type natriuretic peptide; PAPd: End-diastolic pulmonary arterial pres-
PSE: Tricuspid annular plane systolic excursion.
rdiographic parameters BNP mean (pg/mL) p-Values
40 mm Hg 162 ± 96 0.004
20 mm Hg 205 ± 118 0.001
an ≥ 25 mm Hg 128 ± 84 0.001
stolic diameter ≥ 38 mm 179 ± 115 0.001
≤ 16 mm 153 ± 104 0.001
e measurement BNP mean (pg/mL) p-Values
40 mm Hg 169 ± 110 0.02
an ≥ 25 mm Hg 206 ± 127 0.005
pressure ≥ 14 mm Hg 207 ± 151 0.01
Table 3
Logistic regression analysis evaluating ability of echocardiographic parameters (PAPs,
PAPm and TAPSE) and BNP to detect PH. Abbreviations: BNP: B-type natriuretic peptide;
CI: Conﬁdence interval; OR: Odds ratio; PAPs: Pulmonary systolic arterial pressure; PAPm:
Pulmonary arterial pressure mean; PH: Pulmonary hypertension; TAPSE: Tricuspid annu-
lar plane systolic excursion.
OR [CI] p-Value
BNP N 50 pg/mL 11.53 [3.61–24.87] 0.001
PAPs ≥ 40 mm Hg 22.13 [4.47–42.17] 0.003
PAP mean ≥ 25 mm Hg 10.07 [1.17–28.24] 0.04
TAPSE ≤ 16 mm 6.71 [1.72–18.15] 0.006
36 A. Palazzuoli et al. / International Journal of Cardiology 178 (2015) 34–36is the ﬁrst attempt to evaluate the diagnostic role of echocardiography
and BNP levels in patients with ILD and associated PH. Our ﬁndings
showed that BNP is signiﬁcantly correlated to echo-Doppler measure-
ment, particularly those patients with signs of PH or RV dysfunction
evidenced higher BNP values when compared with patients who expe-
rienced normal pressure and RV function. The logistic regression analy-
sis demonstrated that a cutoff of 50 pg/ml for BNP had a good sensibility
and speciﬁcity to recognize subjects with PH. The current non-invasive
data have been validated in the subgroup submitted to right heart cath-
eterization (n = 43) after echocardiographic screening. In these pa-
tients we demonstrated a good correlation between non-invasive and
invasive pressure assessments conﬁrming the role of BNP in the detec-
tion of moderate PAP increase. All together our ﬁndings summarized
previous reports showing that BNP is a good diagnostic indicator for
PH in ILD. Echocardiographywhen used in patientswith a good acoustic
window is a reliable tool to measure PAP and early recognize PH.
Recently a good correlation between hemodynamic and echocardio-
graphic measurements has been evidenced in the current setting [11]
conﬁrming our results. Therefore an algorithm considering laboratory
and echomeasurement could help in the identiﬁcation of those patients
with ILD affected with moderate PH.
BNP has also demonstrated a prognostic impact in patients with ILD
inmore recent studies: in an oriental population Song et al. [12] showed
that a combination of BNP level and PAPs measured by echocardiogra-
phy may provide a better prediction of mortality than either parameter
alone. In another study Corte et al. [13] demonstrated the prognostic
value of BNP and echocardiography over the ILD population as a
whole, independently of the underlying disease severity. Elevated BNP
concentration and pulmonary vascular resistance levels were linked to
increased mortality across ILD patients.
Our data suggest that BNP levels and echocardiography are clinically
useful and easily repeatable tools for mild PH detection in patients with
ILD. If our preliminary results will be conﬁrmed in a larger population,
an algorithm including echocardiographic measurements associatedwith a BNP cutoff N 50 pg/ml should be applied in clinical practice as a
preliminary screening for invasive hemodynamic study selection.
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